中国药物警戒 ›› 2026, Vol. 23 ›› Issue (10): 1171-1174.
DOI: 10.19803/j.1672-8629.20260297

• 安全与合理用药 • 上一篇    下一篇

尼达尼布软胶囊致肺出血1例分析

全秋平1, 陈俊珊1, 邝美丹1,2, 李家春1,2*   

  1. 1广州中医药大学第八临床医学院呼吸内科,广东 佛山 528000;
    2佛山市中医院呼吸内科,广东 佛山 528000
  • 收稿日期:2026-04-13 出版日期:2026-10-15 发布日期:2026-10-16
  • 通讯作者: *李家春,男,本科,副主任中医师,中西医结合治疗呼吸系统疾病。E-mail: 398149605@qq.com
  • 作者简介:全秋平,女,在读硕士,中医内科学呼吸系统。

One case of pulmonary hemorrhage caused by nintedanib soft capsules

Quan Qiuping1, Chen Junshan1, Kuang Meidan1,2, Li Jiachun1,2*   

  1. 1Department of Respiratory Medicine, the Eighth Clinical Medical College of Guangzhou University of Chinese Medicine, Foshan Guangdong 528000, China;
    2Department of Respiratory Medicine, Foshan Hospital of Traditional Chinese Medicine, Foshan Guangdong 528000, China
  • Received:2026-04-13 Online:2026-10-15 Published:2026-10-16

PDF (PC)

39

摘要： 目的 探讨尼达尼布软胶囊治疗进展性肺纤维化致肺出血的临床特征及高危因素,为临床安全用药提供参考。方法 分析1例78岁进展性肺纤维化患者服用2次尼达尼布软胶囊后发生肺出血的病例,结合文献复习,梳理其可能的发生机制及风险因素,并提出防治建议。结果 停用尼达尼布软胶囊并予止血及支持治疗后,患者咯血逐渐减少。经关联性分析,尼达尼布软胶囊与此次肺出血的因果关系为“很可能”。结论 临床使用尼达尼布软胶囊前应审慎评估患者局部肺血管状态及全身状况,密切关注尼达尼布软胶囊的出血风险,必要时减量或延迟使用,用药期间加强不良反应监测,以防范肺出血的发生。

关键词: 尼达尼布软胶囊, 进展性肺纤维化, 肺出血, 药品不良反应

Abstract: Objective To investigate the clinical characteristics of and risk factors for pulmonary hemorrhage induced by nintedanib soft capsules in the treatment of progressive pulmonary fibrosis so as to provide a reference for clinical safe medication. Methods A case of a 78-year-old patient with progressive pulmonary fibrosis who developed pulmonary hemorrhage after two doses of nintedanib soft capsules was analyzed. Based on literature review, the possible mechanism and risk factors were explored, and ways of prevention and treatment were recommended. Results Nintedanib soft capsules were immediately discontinued upon the clinician’s instruction. Following hemostatic and supportive treatments, the patient’s hemoptysis gradually subsided. Based on the correlation analysis, the causal relationship between nintedanib soft capsules and pulmonary hemorrhage was assessed as “probable”. Conclusion Before prescribing nintedanib soft capsules, clinicians should assess the patient’s local pulmonary vascular status and general condition while staying alert to the hemorrhagic risk associated with nintedanib soft capsules. Dose reduction or delayed administration should be considered when necessary. During treatment, adverse drug reactions should be monitored to prevent pulmonary hemorrhage.

Key words: Nintedanib Soft Capsules, Progressive Pulmonary Fibrosis, Pulmonary Hemorrhage, Adverse Drug Reaction

中图分类号: